Associated Genetic Biomarkers
NCI Definition: A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008) 
Essential thrombocythemias most frequently harbor alterations in JAK2, CALR, ASXL1, DNMT3A, and TET2 .
JAK2 V617F, JAK2 Mutation, JAK2 Exon 14 Mutation, CALR Mutation, and CALR L367fs are the most common alterations in essential thrombocythemia .
There are 9 clinical trials for essential thrombocythemia, of which 5 are open and 4 are completed or closed. Of the trials that contain essential thrombocythemia as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (3 open), and 2 are phase 3 (1 open).
Img-7289, anagrelide, and aspirin are the most common interventions in essential thrombocythemia clinical trials.
Significant Genes in Essential Thrombocythemia
JAK2 is altered in 43.56% of essential thrombocythemia patients .
JAK2 is an inclusion eligibility criterion in 3 clinical trials for essential thrombocythemia, of which 0 are open and 3 are closed. Of the trials that contain JAK2 status and essential thrombocythemia as inclusion criteria, 1 is phase 1/phase 2 (0 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.